Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative UFT+LV vs UFT+LV/UFT vs UFT+LV+PSK in Stage III Colorectal Cancer
NCT00209742Phase 3Unknown
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Start
- Apr 2005
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Microbiome-Derived Products
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polysaccharide k and tegafur + uracil in colorectal cancer (CRC) (3 arms), sponsored by Hokkaido Gastrointestinal Cancer Study Group. Primary endpoint: Disease-Free Survival Rate at 3 years. Status: unknown.
02
Drugs
polysaccharide ktegafur + uracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00209742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209742.